Pemphigus: Study finds risk factors for relapse on rituximab
More research needed on optimal dosing schedule, investigators say
People with pemphigus with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, a study shows.